Recommended Products
biological source
goat
Quality Level
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
human
manufacturer/tradename
Calbiochem®
availability
not available in Canada
storage condition
OK to freeze
avoid repeated freeze/thaw cycles
isotype
IgG
shipped in
ambient
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... CFH(3075)
General description
Anti-Factor H, goat polyclonal, recognizes Factor H in human. It is validated for Radial Immunodiffusion and Ouchterlony.
Goat polyclonal antibody supplied as undiluted serum. Recognizes Factor H.
Recognizes Factor H.
Immunogen
Human
purified, human factor H
Application
Radial Immunodiffusion (see comments)
Ouchterlony (≥ undiluted)
Ouchterlony (≥ undiluted)
Packaging
Please refer to vial label for lot-specific concentration.
Warning
Toxicity: Standard Handling (A)
Physical form
Undiluted serum.
Reconstitution
Following initial thaw, aliquot and freeze (-20°C).
Other Notes
This antibody has also been reported to work for radial immunodiffusion. Variables associated with assay conditions will dictate the proper working dilution.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 1
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Martin Ihnatko et al.
Frontiers in medicine, 8, 789972-789972 (2022-01-22)
COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) is a rare complication of adenoviral vector (ChAdOx1 nCoV-19) vaccine administration. It is presented as thrombocytopenia and thrombotic manifestations in various sites, especially in cerebral veins. Pulmonary emboli have been reported rarely. We present a
Federica Bianchi et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 33(11), 12099-12111 (2019-08-24)
The 4 component meningococcus B vaccine (4CMenB) vaccine is the first vaccine containing recombinant proteins licensed for the prevention of invasive meningococcal disease caused by meningococcal serogroup B strains. 4CMenB contains 3 main recombinant proteins, including the Neisseria meningitidis factor
Anuj Pathak et al.
Nature communications, 9(1), 3398-3398 (2018-08-25)
Streptococcus pneumoniae evades C3-mediated opsonization and effector functions by expressing an immuno-protective polysaccharide capsule and Factor H (FH)-binding proteins. Here we use super-resolution microscopy, mutants and functional analysis to show how these two defense mechanisms are functionally and spatially coordinated
Jingyi Li et al.
Frontiers in immunology, 15, 1368322-1368322 (2024-04-01)
Activation of complement through the alternative pathway (AP) has a key role in the pathogenesis of IgA nephropathy (IgAN). We previously showed, by intraperitoneal injection of Lactobacillus casei cell wall extract (LCWE), C57BL/6 mice develop mild kidney damage in association
Daniele Veggi et al.
PLoS pathogens, 16(10), e1008882-e1008882 (2020-10-03)
Neisseria meningitidis serogroup B (MenB) is the leading cause of meningococcal meningitis and sepsis in industrialized countries, with the highest incidence in infants and adolescents. Two recombinant protein vaccines that protect against MenB are now available (i.e. 4CMenB and MenB-fHbp).
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service